{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:27:40Z","timestamp":1789759660139,"version":"4.0.1"},"reference-count":268,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2022,4,1]]},"abstract":"<jats:p>The arena of uveitis deals with a number of entities, which can be infectious or immune mediated. Noninfectious uveitis (NIU) has been managed with corticosteroids and immunosuppressives. However, their prolonged use has side effects limiting clinical utility in the long run. Improved knowledge regarding pathogenesis of uveitis and associated systemic disease has led to a new epoch in the development of treatment strategies, of which biologics are the recent ones. Biologics revolutionized the management of NIU especially uveitis associated with spondyloarthropathy and refractory uveitis. They target inflammation at a molecular level with less side effects. The most widely used are tumor necrosis factor-alpha inhibitors (infliximab and adalimumab). Other drugs include anti-CD20 inhibitors (rituximab), interleukin-6R-inhibitor (tocilizumab), Interleukin-1R-inhibitor (anakinra), Iinterleukin-2-inhibitor (daclizumab), and the list is further increasing. New advances in biologics are the biosimilar molecules, which are biological products that are highly similar to the reference product, and they include Infimab (biosimilar of infliximab), Exemptia or Adfrar (biosimilar of adalimumab), and Intacept or Etacept (biosimilar of etanercept). Other group of biologics are Janus Associated Kinase inhibitors (JAK-inhibitors), which are long-term oral treatment options of rheumatoid arthritis. They inhibit JAKs, which cause activation of signal transducer and activator of transcription (STAT) proteins, and initiate transcription of inflammatory genes. Many inflammatory cytokines that are implicated in pathogenesis of ocular inflammation are known to utilize the JAK\/STAT-signaling pathway, including interleukin-2 (IL-2) and IL-6. Thus, biologics are the future of uveitis treatment with promising results. This article aims to summarize the current knowledge on biologics and their clinical utility in the management of NIU.<\/jats:p>","DOI":"10.1089\/jop.2021.0098","type":"journal-article","created":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T16:38:54Z","timestamp":1644338334000},"page":"203-222","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":17,"title":["Current Knowledge of Biologics in Treatment of Noninfectious Uveitis"],"prefix":"10.1177","volume":"38","author":[{"given":"Simple","family":"Gupta","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Command Hospital, Pune, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Shyamsundar","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Command Hospital, Pune, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4510-0668","authenticated-orcid":false,"given":"Mohini","family":"Agrawal","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Command Hospital, Pune, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Vichare","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Command Hospital, Pune, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyotirmay","family":"Biswas","sequence":"additional","affiliation":[{"name":"Department of Uveitis and Ocular Pathology, Sankara Netralaya, Chennai, India."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,4,6]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-200107000-00005"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2003.06.014"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.07.007"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.08.031"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2010.04.031"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2008.198"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.08.007"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2018-312756"},{"key":"e_1_3_3_10_2","first-page":"67","article-title":"Update on the use of systemic biologic agents in the treatment of noninfectious uveitis","volume":"8","author":"Pasadhika S.","year":"2014","unstructured":"Pasadhika S., , and Rosenbaum J.T. Update on the use of systemic biologic agents in the treatment of noninfectious uveitis. Biologics. 8:67\u201381, 2014.","journal-title":"Biologics"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.2174\/1871528111312010006"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.22336\/rjo.2018.16"},{"key":"e_1_3_3_13_2","first-page":"54","article-title":"A review of biologics for uveitis","volume":"1","author":"Reddy A.K.","year":"2015","unstructured":"Reddy A.K., , and Albini T.A. A review of biologics for uveitis. Retin Today. 1:54\u201356, 2015.","journal-title":"Retin Today"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2015.07.001"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.11.017"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-021-01763-8"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2015.1134581"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.4103\/2320-3897.195296"},{"key":"e_1_3_3_19_2","article-title":"Biologics in uveitis: an update","volume":"3","author":"Magesan K.","year":"2019","unstructured":"Magesan K., , Shah A., , and Biswas J. Biologics in uveitis: an update. Indian J. Inflamm. Res. 3, 1, 2019.","journal-title":"Indian J. Inflamm. Res"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-010-1485-8"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.09.048"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1159\/000328738"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-017-0115-5"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.07.019"},{"issue":"108","key":"e_1_3_3_25_2","first-page":"86","article-title":"Infliximab for uveitis of Beh\u00e7et's syndrome: a trend for earlier initiation","volume":"35","author":"Guzelant G.","year":"2017","unstructured":"Guzelant G., , Ucar D., , Esatoglu S.N., et al. Infliximab for uveitis of Beh\u00e7et's syndrome: a trend for earlier initiation. Clin. Exp. Rheumatol. 35(Suppl 108):86\u201389, 2017.","journal-title":"Clin. Exp. Rheumatol"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2008.09.010"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq366"},{"issue":"45","key":"e_1_3_3_28_2","first-page":"S65","article-title":"Infliximab treatment-induced formation of autoantibodies is common in Beh\u00e7et's disease","volume":"25","author":"Elezoglou A.","year":"2007","unstructured":"Elezoglou A., , Kafasi N., , Kaklamanis P.H., et al. Infliximab treatment-induced formation of autoantibodies is common in Beh\u00e7et's disease. Clin. Exp. Rheumatol. 25(4 Suppl 45):S65\u2013S69, 2007.","journal-title":"Clin. Exp. Rheumatol"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-011-1908-1"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.01.005"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.08.018"},{"key":"e_1_3_3_32_2","first-page":"46","article-title":"Use of biologic agents in the treatment of uveitis","volume":"3","author":"Pasadhika S.","year":"2010","unstructured":"Pasadhika S., , Suhler E.B., , and Cunningham E.T. Use of biologic agents in the treatment of uveitis. Rev. Ophthalmol. 3:46\u201352, 2010.","journal-title":"Rev. Ophthalmol"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20404"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.08.031"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2018-312767"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200565040-00005"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2011-301401"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3480-x"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-011-9430-3"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem356"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1186\/1546-0096-11-16"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2010.483314"},{"key":"e_1_3_3_43_2","first-page":"458","article-title":"Long-term control of non-infectious paediatric panuveitis refractory to traditional immunesuppressive therapy, successfully treated with Adalimumab (HumiraTM)","volume":"31","author":"Neri P.","year":"2013","unstructured":"Neri P., , Eandi C., , Arapi I., , Posarelli C., , Mariotti C., , and Giovannini A. Long-term control of non-infectious paediatric panuveitis refractory to traditional immunesuppressive therapy, successfully treated with Adalimumab (HumiraTM). Clin. Exp. Rheumatol. 31:458\u2013462, 2013.","journal-title":"Clin. Exp. Rheumatol"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-013-9801-z"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-15-14"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2017.1288097"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614160"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-013-2275-x"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2017-311234"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2019.1698754"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.02.018"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2018-312756"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509852"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31339-3"},{"key":"e_1_3_3_55_2","first-page":"68","article-title":"Long-term safety and efficacy of adalimumab in patients with non-infectious intermediate, posterior, or panuveitis in an ongoing open-label study [abstract no. 1335]","author":"Suhler E.B.","year":"2016","unstructured":"Suhler E.B., , Jaffe G.J., , Nguyen Q.D., et al. Long-term safety and efficacy of adalimumab in patients with non-infectious intermediate, posterior, or panuveitis in an ongoing open-label study [abstract no. 1335]. Arthritis Rheumatol. 68, 2016.","journal-title":"Arthritis Rheumatol"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.12.039"},{"key":"e_1_3_3_57_2","author":"Bitossi A.","year":"2019","unstructured":"Bitossi A., , Bettiol A., , Silvestri E., , Di Scala G., , Bacherini D., , Lopalco G., , Venerito V., , Iannone F., , Vitale A., , Tosi G.M., , and Prisco D. Adalimumab accounts for long-term control of noninfectious uveitis also in the absence of concomitant DMARD treatment: a multicenter retrospective study. Mediat. Inflamm. 2019, 1623847, 2019.","journal-title":"Mediat. Inflamm"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.39667"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.41026"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4228-6"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171006"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.103192"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2014.993024"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.04.038"},{"key":"e_1_3_3_65_2","first-page":"233","article-title":"Scleritis: a paradoxical effect of etanercept?","volume":"39","author":"Gaujoux-Viala C.","year":"2012","unstructured":"Gaujoux-Viala C., , Giampietro C., , Gaujoux T., , Ea H.K., , Prati C., , Orcel P., et al. Scleritis: a paradoxical effect of etanercept?. Etanercept-associated inflammatory eye disease. J. Rheumatol. 39:233\u2013239, 2012.","journal-title":"Etanercept-associated inflammatory eye disease"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2011.05.005"},{"key":"e_1_3_3_67_2","first-page":"bcr2013200552","article-title":"Sarcoid panuveitis associated with etanercept treatment, resolving with adalimumab","volume":"2013","author":"Dragnev D.","year":"2013","unstructured":"Dragnev D., , Barr D., , Kulshrestha M., , and Shanmugalingam S. Sarcoid panuveitis associated with etanercept treatment, resolving with adalimumab. Case Rep. 2013:bcr2013200552, 2013.","journal-title":"Case Rep"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/471319"},{"key":"e_1_3_3_69_2","article-title":"Golimumab for uveitis","author":"Cordero-Coma M.","unstructured":"Cordero-Coma M., , Salom D., , Diaz-Llopis M., , Lopez-Prats M.J., , and Calleja S. Golimumab for uveitis. Ophthalmology. 118:1892.e3\u2013e4, 2011.","journal-title":"Ophthalmology"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2012.741744"},{"key":"e_1_3_3_71_2","first-page":"95","article-title":"Golimumab in refractory uveitis related to spondyloarthritis","volume":"46","author":"Calvo-R\u0131\u00b4o V","year":"2016","unstructured":"Calvo-R\u0131\u00b4o V, , Blanco R., , Santos-Go\u00b4mez M, , Rubio-Romero E., , Cordero-Coma M., , Gallego- Flores A., , Veroz R., , Torre I., , Herna\u00b4ndez FF, , Atanes A., , Loricera J., , Gonza \u00b4lez-Vela M.C., , Palmou N., , Herna\u00b4ndez JL, , and Gonza\u00b4- lez-Gay M.A. Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients. Semin. Arthritis Rheum. 46:95\u2013101, 2016.","journal-title":"Multicenter study of 15 patients"},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.12207"},{"key":"e_1_3_3_73_2","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2017.1351573"},{"key":"e_1_3_3_74_2","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2017.1285857"},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.1159\/000495655"},{"key":"e_1_3_3_76_2","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001161"},{"key":"e_1_3_3_77_2","first-page":"680","article-title":"Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis","volume":"37","author":"Tosi G.M.","year":"2019","unstructured":"Tosi G.M., , Sota J., , Vitale A., , Rigante D., , Emmi G., , Lopalco G., , Guerriero S., , Orlando I., , Iannone F., , Frediani B., , and Angotti R. Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis. Clin. Exp. Rheumatol. 37:680\u2013683, 2019.","journal-title":"Clin. Exp. Rheumatol"},{"key":"e_1_3_3_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2020.100633"},{"key":"e_1_3_3_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2008.06.012"},{"key":"e_1_3_3_80_2","first-page":"74","article-title":"Biologic therapy for posterior uveitis and panuveitis","volume":"4","author":"Pasadhika S.","year":"2012","unstructured":"Pasadhika S., , Suhler E.B., , and Cunningham E.T. Biologic therapy for posterior uveitis and panuveitis. Retina Today. 4:74\u201379, 2012.","journal-title":"Retina Today"},{"key":"e_1_3_3_81_2","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2011.644383"},{"key":"e_1_3_3_82_2","first-page":"2188","article-title":"Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy","volume":"54","author":"Furst D.E.","year":"2015","unstructured":"Furst D.E., , Kavanaugh A., , Florentinus S., , Kupper H., , Karunaratne M., , and Birbara C.A. Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy. Rheumatol (United Kingdom). 54:2188\u20132197, 2015.","journal-title":"Rheumatol (United Kingdom)"},{"key":"e_1_3_3_83_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0516-6"},{"key":"e_1_3_3_84_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.08-2370"},{"key":"e_1_3_3_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.12.015"},{"key":"e_1_3_3_86_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.105775"},{"key":"e_1_3_3_87_2","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.13511"},{"key":"e_1_3_3_88_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3506-4"},{"key":"e_1_3_3_89_2","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2018.1511810"},{"key":"e_1_3_3_90_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.016014"},{"key":"e_1_3_3_91_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2006.0101477"},{"key":"e_1_3_3_92_2","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2014.861325"},{"key":"e_1_3_3_93_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01157"},{"key":"e_1_3_3_94_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102152"},{"key":"e_1_3_3_95_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160231"},{"key":"e_1_3_3_96_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12348-019-0182-y"},{"key":"e_1_3_3_97_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2017.08.019"},{"key":"e_1_3_3_98_2","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2015.1129692"},{"key":"e_1_3_3_99_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160908"},{"key":"e_1_3_3_100_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex480"},{"key":"e_1_3_3_101_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001690"},{"key":"e_1_3_3_102_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2018.12.019"},{"key":"e_1_3_3_103_2","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_1938_18"},{"key":"e_1_3_3_104_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30008-4"},{"key":"e_1_3_3_105_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30035-7"},{"key":"e_1_3_3_106_2","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2020.1712431"},{"key":"e_1_3_3_107_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-8411(03)00113-6"},{"key":"e_1_3_3_108_2","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2007.49"},{"key":"e_1_3_3_109_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2008.05.001"},{"key":"e_1_3_3_110_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2009.06.003"},{"key":"e_1_3_3_111_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjo.2011.06.008"},{"key":"e_1_3_3_112_2","doi-asserted-by":"publisher","DOI":"10.1080\/09273940701299370"},{"key":"e_1_3_3_113_2","unstructured":"Brooks M. MS drug daclizumab (zinbryta) pulled from the market. 2018. Available at: www.medscape.com\/viewarticle\/893352. Accessed February1 2019"},{"key":"e_1_3_3_114_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.05.014"},{"key":"e_1_3_3_115_2","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/7617954"},{"key":"e_1_3_3_116_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2015.5934"},{"key":"e_1_3_3_117_2","first-page":"130","article-title":"Ustekinumab efficacy and safety in mucocutaneous multi-refractory Beh\u00e7et's disease","volume":"35","author":"Lopalco G.","year":"2017","unstructured":"Lopalco G., , Fabiani C., , Venerito V., , Lapadula G., , Iannone F., , and Cantarini L. Ustekinumab efficacy and safety in mucocutaneous multi-refractory Beh\u00e7et's disease. Clin. Exp. Rheumatol. 35:130\u2013131, 2017.","journal-title":"Clin. Exp. Rheumatol"},{"key":"e_1_3_3_118_2","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12527"},{"key":"e_1_3_3_119_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjz167"},{"key":"e_1_3_3_120_2","first-page":"5948","article-title":"Efficacy of IL-12\/23 inhibition for the Treatment of Active Sight-Threatening Uveitis: a Pilot Study","volume":"59","author":"Utriainen L.","year":"2018","unstructured":"Utriainen L., , Lee J.W., , Li Z., , Chaon B., , Thompson I., , Chaigne-Delalande B., , and Sen H.N. Efficacy of IL-12\/23 inhibition for the Treatment of Active Sight-Threatening Uveitis: a Pilot Study. Invest. Ophthalmol. Vis. Sci. 59:5948, 2018.","journal-title":"Invest. Ophthalmol. Vis. Sci"},{"key":"e_1_3_3_121_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100866"},{"key":"e_1_3_3_122_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31279-5"},{"key":"e_1_3_3_123_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15750"},{"key":"e_1_3_3_124_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30952-8"},{"key":"e_1_3_3_125_2","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2019.1569245"},{"key":"e_1_3_3_126_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.03.049"},{"key":"e_1_3_3_127_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607017"},{"key":"e_1_3_3_128_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30570-6"},{"key":"e_1_3_3_129_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31429-0"},{"key":"e_1_3_3_130_2","doi-asserted-by":"publisher","DOI":"10.1159\/000479475"},{"key":"e_1_3_3_131_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0724-2"},{"key":"e_1_3_3_132_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204405"},{"key":"e_1_3_3_133_2","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2017.1351297"},{"key":"e_1_3_3_134_2","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2017-0075"},{"key":"e_1_3_3_135_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.09.044"},{"key":"e_1_3_3_136_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204963"},{"key":"e_1_3_3_137_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200704"},{"key":"e_1_3_3_138_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204760"},{"key":"e_1_3_3_139_2","doi-asserted-by":"publisher","DOI":"10.1097\/APO.0b013e318294b850"},{"key":"e_1_3_3_140_2","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2015.1092558"},{"key":"e_1_3_3_141_2","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2017.1421233"},{"key":"e_1_3_3_142_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3001107"},{"key":"e_1_3_3_143_2","first-page":"939","article-title":"AIN457A2208 Study Group","volume":"122","author":"Letko E.","year":"2015","unstructured":"Letko E., , Yeh S., , Foster C.S., , Pleyer U., , Brigell M., , and Grosskreutz C.L. AIN457A2208 Study Group. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy. Ophthalmology. 122:939\u2013948, 2015.","journal-title":"Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy"},{"key":"e_1_3_3_144_2","doi-asserted-by":"publisher","DOI":"10.4103\/0301-4738.194339"},{"key":"e_1_3_3_145_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.09.040"},{"key":"e_1_3_3_146_2","doi-asserted-by":"publisher","DOI":"10.1093\/omcr\/omz041"},{"key":"e_1_3_3_147_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11139"},{"key":"e_1_3_3_148_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14493"},{"key":"e_1_3_3_149_2","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.298"},{"key":"e_1_3_3_150_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201383"},{"key":"e_1_3_3_151_2","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2018.1511810"},{"key":"e_1_3_3_152_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160064"},{"key":"e_1_3_3_153_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2007.133173"},{"key":"e_1_3_3_154_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-015-0128-2"},{"key":"e_1_3_3_155_2","doi-asserted-by":"publisher","DOI":"10.1159\/000486791"},{"key":"e_1_3_3_156_2","doi-asserted-by":"publisher","DOI":"10.3109\/09273941003739928"},{"key":"e_1_3_3_157_2","first-page":"365","article-title":"Rytuksymab w leczeniu chorych na reumatoidalne zapalenie staw\u00f3w po niepowodzeniu terapii inhibitorami TNF-alpha [Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy in Poland]","volume":"29","author":"Samborski W.","year":"2010","unstructured":"Samborski W., , Buczek J., , Bednarek A., , Lewandowicz J., , and Kucharz E. Rytuksymab w leczeniu chorych na reumatoidalne zapalenie staw\u00f3w po niepowodzeniu terapii inhibitorami TNF-alpha [Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy in Poland]. Pol. Merkur. Lekarski. 29:365\u2013368, 2010.","journal-title":"Pol. Merkur. Lekarski"},{"key":"e_1_3_3_158_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2015-306790"},{"key":"e_1_3_3_159_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001563"},{"key":"e_1_3_3_160_2","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-008-0057-9"},{"key":"e_1_3_3_161_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-014-2781-1"},{"key":"e_1_3_3_162_2","first-page":"31","article-title":"Abatacept for the treatment of adults with psoriatic arthritis: patient selection and perspectives","volume":"8","author":"Noisette A.","year":"2018","unstructured":"Noisette A., , and Hochberg M.C. Abatacept for the treatment of adults with psoriatic arthritis: patient selection and perspectives. Psoriasis (Auckl). 8:31\u201339, 2018.","journal-title":"Psoriasis (Auckl)"},{"key":"e_1_3_3_163_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140410"},{"key":"e_1_3_3_164_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-015-3140-x"},{"key":"e_1_3_3_165_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151389"},{"key":"e_1_3_3_166_2","first-page":"5190","article-title":"A Phase I\/II Dose-Ranging, Randomized Clinical Trial of Abatacept (Orencia) in the Treatment of Refractory Non-Infectious Uveitis: preliminary Results","volume":"54","author":"Suhler E.","year":"2013","unstructured":"Suhler E., , Giles T., , Hanel S., , Liesegang T., , Beardsley R., , Larkin K., , Lin P., , and Rosenbaum J. A Phase I\/II Dose-Ranging, Randomized Clinical Trial of Abatacept (Orencia) in the Treatment of Refractory Non-Infectious Uveitis: preliminary Results. Invest. Ophthalmol. Vis. Sci. 54:5190-, 2013.","journal-title":"Invest. Ophthalmol. Vis. Sci"},{"key":"e_1_3_3_167_2","first-page":"409","article-title":"Efficacy of abatacept treatment for severe, recalcitrant pediatric uveitis","volume":"59","author":"Naqvi S.M.","year":"2018","unstructured":"Naqvi S.M., , Utz V.M., , Bulas S., , Dan L., , Lopper S., , and Kaufman A.H. Efficacy of abatacept treatment for severe, recalcitrant pediatric uveitis. Invest. Ophthalmol. Vis. Sci. 59:409-, 2018.","journal-title":"Invest. Ophthalmol. Vis. Sci"},{"key":"e_1_3_3_168_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.84.1.107"},{"key":"e_1_3_3_169_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-1188-6"},{"key":"e_1_3_3_170_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.141344"},{"key":"e_1_3_3_171_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-016-0370-9"},{"key":"e_1_3_3_172_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-5896"},{"key":"e_1_3_3_173_2","doi-asserted-by":"publisher","DOI":"10.1159\/000326111"},{"key":"e_1_3_3_174_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw092"},{"key":"e_1_3_3_175_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215739"},{"key":"e_1_3_3_176_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215734"},{"key":"e_1_3_3_177_2","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy065"},{"key":"e_1_3_3_178_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-018-4971-1"},{"key":"e_1_3_3_179_2","first-page":"75","article-title":"Vedolizumab-Induced De Novo Extraintestinal Manifestations","volume":"16","author":"Diaz L.I.","year":"2020","unstructured":"Diaz L.I., , Keihanian T., , Schwartz I., , Kim S.B., , Calmet F., , Quintero M.A., , and Abreu M.T. Vedolizumab-Induced De Novo Extraintestinal Manifestations. Gastroenterol. Hepatol. 16:75, 2020.","journal-title":"Gastroenterol. Hepatol"},{"key":"e_1_3_3_180_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI35636"},{"key":"e_1_3_3_181_2","first-page":"65","article-title":"Future Therapies for chronic noninfectious Uveitis","author":"Cunningham E.T.","year":"2012","unstructured":"Cunningham E.T. Future Therapies for chronic noninfectious Uveitis. Retin Today. 65\u201374, 2012.","journal-title":"Retin Today"},{"key":"e_1_3_3_182_2","unstructured":"Safety tolerability and efficacy of AEB071 in the treatment of uveitis. Available at: https:\/\/clinicaltrials.gov\/show\/NCT00615693. Accessed June18 2015."},{"key":"e_1_3_3_183_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-020-01496-0"},{"key":"e_1_3_3_184_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms13021886"},{"key":"e_1_3_3_185_2","doi-asserted-by":"publisher","DOI":"10.1159\/000438951"},{"key":"e_1_3_3_186_2","doi-asserted-by":"publisher","DOI":"10.2174\/1381612823666170111125550"},{"key":"e_1_3_3_187_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2004.048199"},{"key":"e_1_3_3_188_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.12.018"},{"key":"e_1_3_3_189_2","doi-asserted-by":"publisher","DOI":"10.1186\/1869-5760-3-32"},{"key":"e_1_3_3_190_2","first-page":"2025","article-title":"Combination Daclizumab\/Sirolimus Therapy for the Induction of Immune Tolerance in Non-Infectious Intermediate and Posterior Uveitis","volume":"50","author":"Wroblewski K.J.","year":"2009","unstructured":"Wroblewski K.J., , Sen H., , Faia L., , Yeh S., , Nussenblatt R.B., , and Ragheb J. Combination Daclizumab\/Sirolimus Therapy for the Induction of Immune Tolerance in Non-Infectious Intermediate and Posterior Uveitis. Invest. Ophthalmol. Vis. Sci.. 50:2025-, 2009.","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"e_1_3_3_191_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.07.029"},{"key":"e_1_3_3_192_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S198401"},{"key":"e_1_3_3_193_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.23.021704.115843"},{"key":"e_1_3_3_194_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2006.101550"},{"key":"e_1_3_3_195_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2008.153874"},{"key":"e_1_3_3_196_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2017.03.001"},{"key":"e_1_3_3_197_2","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2019.1604001"},{"key":"e_1_3_3_198_2","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2019.1589526"},{"key":"e_1_3_3_199_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2003.09.010"},{"key":"e_1_3_3_200_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2008.08.038"},{"key":"e_1_3_3_201_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2011.0238"},{"key":"e_1_3_3_202_2","first-page":"599","article-title":"Potential of pegylated interferon alpha-2a in Beh\u00e7et uveitis: a report of five cases","volume":"24","author":"Bielefeld P.","year":"2016","unstructured":"Bielefeld P., , Devilliers H., , Deschasse C., , Saadoun D., , S\u00e8ve P., , Muselier A., , Creuzot-Garcher C., , Besancenot J.F., , and Bron A.M. Potential of pegylated interferon alpha-2a in Beh\u00e7et uveitis: a report of five cases. Ocul. Immunol. Inflamm. 24:599\u2013602, 2016.","journal-title":"Ocul. Immunol. Inflamm"},{"key":"e_1_3_3_203_2","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2015.1133835"},{"key":"e_1_3_3_204_2","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2017.1384026"},{"key":"e_1_3_3_205_2","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2019.1606256"},{"key":"e_1_3_3_206_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2013.05.002"},{"key":"e_1_3_3_207_2","doi-asserted-by":"publisher","DOI":"10.4274\/tjo.35555"},{"key":"e_1_3_3_208_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1590-8658(04)80002-1"},{"key":"e_1_3_3_209_2","first-page":"599","article-title":"Potential of pegylated interferon alpha-2a in Beh\u00e7et uveitis: a report of five cases","volume":"24","author":"Bielefeld P.","year":"2016","unstructured":"Bielefeld P., , Devilliers H., , Deschasse C., , Saadoun D., , S\u00e8ve P., , Muselier A., , Creuzot-Garcher C., , Besancenot J.F., , and Bron A.M. Potential of pegylated interferon alpha-2a in Beh\u00e7et uveitis: a report of five cases. Ocul. Immunol. Inflamm. 24:599\u2013602, 2016.","journal-title":"Ocul. Immunol. Inflamm"},{"key":"e_1_3_3_210_2","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2019.1604001"},{"key":"e_1_3_3_211_2","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.00963"},{"issue":"1","key":"e_1_3_3_212_2","first-page":"i43","article-title":"JAK-inhibitors","volume":"58","author":"Fragoulis G.E.","year":"2019","unstructured":"Fragoulis G.E., , McInnes I.B., , and Siebert S. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology. 58(Suppl_1):i43\u2013i54, 2019.","journal-title":"New players in the field of immune-mediated diseases, beyond rheumatoid arthritis"},{"key":"e_1_3_3_213_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.23"},{"key":"e_1_3_3_214_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.12.005"},{"key":"e_1_3_3_215_2","first-page":"5350","article-title":"Efficacy of Targeted Janus Kinase (JAK) Inhibition by Tofacitinib in Birdshot Chorioretinitis","volume":"61","author":"Hassman L.M.","year":"2020","unstructured":"Hassman L.M., , Paley M., , Esaulova E., , Laurent J., , Springer L., , Artyomov M., , and Yokoyama W. Efficacy of Targeted Janus Kinase (JAK) Inhibition by Tofacitinib in Birdshot Chorioretinitis. Invest. Ophthalmol. Vis. Sci. 61:5350-, 2020.","journal-title":"Invest. Ophthalmol. Vis. Sci"},{"key":"e_1_3_3_216_2","first-page":"396","article-title":"YJ, Do, D.V., and Nguyen, Q.D","volume":"47","author":"Hassan M.","year":"2019","unstructured":"Hassan M., , Karkhur S., , Bae J.H., , Halim M.S., , Ormaechea M.S., , Onghanseng N., , Nguyen N.V., , Afridi R., Sepah 203. YJ, Do, D.V., and Nguyen, Q.D. New therapies in development for the management of non-infectious uveitis: a review. Clin. Exp. Ophthalmol.. 47:396\u2013417, 2019.","journal-title":"New therapies in development for the management of non-infectious uveitis: a review"},{"key":"e_1_3_3_217_2","unstructured":"Tofacitinib for Inflammatory Eye Disease - Full Text View - ClinicalTrials.gov. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03580343. Accessed 8 May 2020"},{"key":"e_1_3_3_218_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2018.12.001"},{"key":"e_1_3_3_219_2","first-page":"5350","article-title":"Efficacy of Targeted Janus Kinase (JAK) Inhibition by Tofacitinib in Birdshot Chorioretinitis","volume":"61","author":"Hassman L.M.","year":"2020","unstructured":"Hassman L.M., , Paley M., , Esaulova E., , Laurent J., , Springer L., , Artyomov M., , and Yokoyama W. Efficacy of Targeted Janus Kinase (JAK) Inhibition by Tofacitinib in Birdshot Chorioretinitis. Invest. Ophthalmol. Vis. Sci. 61:5350-, 2020.","journal-title":"Invest. Ophthalmol. Vis. Sci"},{"key":"e_1_3_3_220_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210104"},{"key":"e_1_3_3_221_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210105"},{"key":"e_1_3_3_222_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32537-5"},{"key":"e_1_3_3_223_2","unstructured":"Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis Full Text View - ClinicalTrials.gov. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03207815. Accessed 8 May 2020."},{"key":"e_1_3_3_224_2","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2018-0178"},{"key":"e_1_3_3_225_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04875-w"},{"key":"e_1_3_3_226_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2019.06.004"},{"key":"e_1_3_3_227_2","doi-asserted-by":"publisher","DOI":"10.1210\/er.2007-0027"},{"key":"e_1_3_3_228_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2016.09.004"},{"key":"e_1_3_3_229_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2019.100502"},{"key":"e_1_3_3_230_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2018.0090"},{"key":"e_1_3_3_231_2","unstructured":"ACTH as A Re-emerging the rapy for uveitis (The ACTHAR Study) - Full TextView -ClinicalTrials.gov. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02931175. Accessed 8 May 2020."},{"key":"e_1_3_3_232_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2018.07.013"},{"key":"e_1_3_3_233_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200535500"},{"key":"e_1_3_3_234_2","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2012.681830"},{"key":"e_1_3_3_235_2","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2009.32"},{"key":"e_1_3_3_236_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep40414"},{"key":"e_1_3_3_237_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0041-4"},{"key":"e_1_3_3_238_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.07.116"},{"key":"e_1_3_3_239_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2016.0165"},{"key":"e_1_3_3_240_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2016.0165"},{"key":"e_1_3_3_241_2","first-page":"3233","article-title":"Human S-antigen determinant recognition in uveitis","volume":"42","author":"De Smet M.D.","year":"2001","unstructured":"De Smet M.D., , Bitar G., , Mainigi S., , and Nussenblatt R.B. Human S-antigen determinant recognition in uveitis. Invest. Ophthalmol. Vis. Sci. 42:3233\u20133238, 2001.","journal-title":"Invest. Ophthalmol. Vis. Sci"},{"key":"e_1_3_3_242_2","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1309.048"},{"key":"e_1_3_3_243_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2009.09.011"},{"key":"e_1_3_3_244_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.155.8.4090"},{"key":"e_1_3_3_245_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.8.5423"},{"key":"e_1_3_3_246_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2000.20229"},{"key":"e_1_3_3_247_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2000.20196"},{"key":"e_1_3_3_248_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.49.1.42"},{"key":"e_1_3_3_249_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2010.08.002"},{"key":"e_1_3_3_250_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4176"},{"key":"e_1_3_3_251_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202677"},{"key":"e_1_3_3_252_2","doi-asserted-by":"crossref","first-page":"e0154904","DOI":"10.1371\/journal.pone.0154904","article-title":"The role of interleukin-22 and its receptor in the development and pathogenesis of experimental autoimmune uveitis","volume":"11","author":"Kim Y.","year":"2016","unstructured":"Kim Y., , Kim T.W., , Park Y.S., , Jeong E.M., , Lee D.S., , Kim I.G., , Chung H., , Hwang Y.I., , Lee W.J., , Yu H.G., , and Kang J.S. The role of interleukin-22 and its receptor in the development and pathogenesis of experimental autoimmune uveitis. PLoS One. 11:e0154904, 2016.","journal-title":"PLoS One"},{"key":"e_1_3_3_253_2","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2013.770888"},{"key":"e_1_3_3_254_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.7.5147"},{"key":"e_1_3_3_255_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000466"},{"key":"e_1_3_3_256_2","first-page":"835","article-title":"Results of intravitreal dexamethasone implant 0.7\u2009mg (Ozurdex\u00ae) in non-infectious posterior uveitis","volume":"8","author":"Yap Y.C.","year":"2015","unstructured":"Yap Y.C., , Papathomas T., , and Kamal A. Results of intravitreal dexamethasone implant 0.7\u2009mg (Ozurdex\u00ae) in non-infectious posterior uveitis. Int. J. Ophthalmol. 8:835, 2015.","journal-title":"Int. J. Ophthalmol"},{"key":"e_1_3_3_257_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181d3758a"},{"key":"e_1_3_3_258_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2012.03.035"},{"key":"e_1_3_3_259_2","first-page":"2399","article-title":"Intravitreal Infliximab in refractory uveitis in Behcet's Disease","volume":"36","author":"Hamza M.M.E.","year":"2016","unstructured":"Hamza M.M.E., , Macky T.A., , Sidky M.K., , Ragab G., , and \u2020Soliman M.M. Intravitreal Infliximab in refractory uveitis in Behcet's Disease. A safety and efficacy clinical study. Retina. 36:2399\u20132408, 2016.","journal-title":"A safety and efficacy clinical study"},{"key":"e_1_3_3_260_2","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2017.1335756"},{"key":"e_1_3_3_261_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-017-0592-5"},{"key":"e_1_3_3_262_2","first-page":"319","article-title":"Intravitreal adalimumab in active noninfectious uveitis: a pilot study","volume":"24","author":"Hamam R.N.","year":"2016","unstructured":"Hamam R.N., , Barikian A.W., , Antonios R.S., , Abdulaal M.R., , Alameddine R.M., , El Mollayess G., , and Mansour A.M. Intravitreal adalimumab in active noninfectious uveitis: a pilot study. Ocul. Immunol. Inflamm. 24:319\u2013326, 2016.","journal-title":"Ocul. Immunol. Inflamm"},{"key":"e_1_3_3_263_2","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.4.2.4"},{"key":"e_1_3_3_264_2","first-page":"T3","article-title":"The effect of different dosing schedules of intravitreal sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, in the treatment of non-infectious uveitis (an American Ophthalmological Society thesis)","volume":"114","author":"Nguyen Q.D.","year":"2016","unstructured":"Nguyen Q.D., , Sadiq M.A., , Soliman M.K., , Agarwal A., , Do D.V., , and Sepah Y.J. The effect of different dosing schedules of intravitreal sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, in the treatment of non-infectious uveitis (an American Ophthalmological Society thesis). Trans. Am. Ophthalmol. Soc. 114:T3, 2016.","journal-title":"Trans. Am. Ophthalmol. Soc"},{"key":"e_1_3_3_265_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.06.015"},{"key":"e_1_3_3_266_2","doi-asserted-by":"publisher","DOI":"10.4103\/tjosr.tjosr_14_19"},{"key":"e_1_3_3_267_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.03.033"},{"key":"e_1_3_3_268_2","first-page":"81","article-title":"Emerging Treatments for Non-infectious Uveitis","volume":"11","author":"Banker A.S.","year":"2018","unstructured":"Banker A.S., , Pavesio C., , and Merrill P. Emerging Treatments for Non-infectious Uveitis. US Ophthalmic Rew. 11:81\u201386, 2018.","journal-title":"US Ophthalmic Rew"},{"key":"e_1_3_3_269_2","doi-asserted-by":"publisher","DOI":"10.4103\/0301-4738.185605"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2021.0098","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2021.0098","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2021.0098","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:44:49Z","timestamp":1777646689000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2021.0098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":268,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,4,1]]}},"alternative-id":["10.1089\/jop.2021.0098"],"URL":"https:\/\/doi.org\/10.1089\/jop.2021.0098","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,1]]}}}